Anchalee Avihingsanon | Pharmaceutical Policy and Regulation | Best Researcher Award

Published on by Top Pharmaceutical

Anchalee Avihingsanon | Pharmaceutical Policy and Regulation | Best Researcher Award

Dr. Anchalee Avihingsanon, HIV-NAT, Thai Red Cross AIDS and Infectious Diseases Research Collaboration, Thailand

Dr. Anchalee Avihingsanon, MD, PhD šŸ©ŗšŸ”¬ is a distinguished infectious disease specialist with over 20 years of expertise in HIV/AIDS, tuberculosis, and viral hepatitis research. She leads the HIV-NAT clinical research program at the Thai Red Cross AIDS and Infectious Disease Research Centre in Bangkok šŸ‡¹šŸ‡­ and serves as Clinical Research Site Leader for ACTG. Dr. Avihingsanon actively shapes national health policies in Thailand and contributes to WHO guideline development šŸŒ. Her international research spans clinical trials addressing HIV, TB, and emerging infections. She has earned numerous awards for her impactful work in resource-limited settings.

Publication Profile

Orcid

Education

Dr. Anchalee Avihingsanon completed her medical degree (MD) at Khon Kaen University, Thailand, from 1986 to 1992. She then specialized in Internal Medicine at Chulalongkorn University, Bangkok, during 1994-1996, followed by a focus on Infectious Disease from 1998 to 1999 at the same institution. Dr. Avihingsanon advanced her expertise as a research fellow in Infectious Diseases at Beth Israel Deaconess Medical Center in Boston, USA, from 2000 to 2002. She earned her PhD in HIV and Coinfection at Amsterdam University, The Netherlands, between 2011 and 2013.

Experience

Dr. Anchalee Avihingsanon has been actively involved in numerous professional roles since 1999. She currently serves as the ACTG Regional Representative for Asia and is a key member of several WHO advisory groups on HIV, viral hepatitis, and STIs. She is also an infectious disease expert on Bangkokā€™s Essential Medicine Committee and contributes to national efforts on AIDS, TB, and hepatitis. Dr. Avihingsanon participates in multiple research and guideline committees, including the Thai Ministry of Public Health and international scientific groups. She holds memberships in prestigious organizations like the International AIDS Society and the Royal College of Physicians.

Awards

Dr. Anchalee Avihingsanon has received numerous honors throughout her career. In 2016, she successfully passed the US-FDA inspection for key studies. She was awarded the Australia-APEC Women in Research Fellowship in 2015 and received the prestigious NUFFIC PhD grant from the Netherlands Embassy during 2011-2013. Dr. Avihingsanon earned scholarships to attend global workshops and conferences, including the European AIDS Conference and International AIDS Society from 2007 to 2022. Early in her career, she was recognized as Best Doctor at Samutsakorn Hospital in 1998 and served as chief resident at King Chulalongkorn Memorial Hospital in 1997.

Research Focus

Dr. Anchalee Avihingsanon is a distinguished researcher specializing in HIV and Hepatitis C co-infections, with a strong focus on antiretroviral therapy optimization, pharmacokinetics, and treatment outcomes. Her work includes evaluating minimal monitoring HCV treatments, assessing drug interactions in people living with HIV, and improving health-related quality of life for patients. She also investigates malnutrition, sarcopenia risks in elderly HIV patients, and liver fibrosis progression using advanced diagnostics. Anchaleeā€™s contributions significantly impact infectious disease management, particularly in Asian populations, aiming to enhance therapy safety, efficacy, and accessibility.

Publication Top Notes

Impact of a minimal monitoring HCV treatment approach on Health-Related Quality of Life
The population pharmacokinetics of dolutegravir coā€administered with rifampicin in Thai people living with HIV: Assessment of alternative dosing regimens
Performance of ElecsysĀ® HCV Duo Immunoassay for Diagnosis and Assessment of Treatment Response in HCV Patients with or without HIV Infection
The Risk of Malnutrition and Sarcopenia in Elderly People Living with HIV during the COVID-19 Pandemic
Pharmacokinetics of Sofosbuvir/Velpatasvir and efficacy of an alternateā€day treatment in hemodialysis patients with chronic hepatitis C infection
Efficacy and safety of switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed Asian adults living with HIV: A pooled analysis from three international phase III randomized trials
The 25th Bangkok International Symposium on HIV Medicine
Dose optimization with population pharmacokinetics of ritonavir-boosted lopinavir for Thai people living with HIV with and without active tuberculosis
Conference Proceedings from the Virtual 24th Bangkok International Symposium on HIV Medicine
Thirdā€line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resourceā€limited settings: ACTG A5288 strategy trial

Ashenafi Sendekie | Pharmaceutical Policy and Regulation | Best Researcher Award

Published on by Top Pharmaceutical

Ashenafi Sendekie | Pharmaceutical Policy and Regulation | Best Researcher Award

Mr Ashenafi Sendekie, Curtin University, Australia

Mr. Ashenafi Kibret Sendekie is a dedicated researcher and academic pursuing a Ph.D. at Curtin University, focusing on ethical dilemmas in pharmacist-administered vaccinations for children and adolescents. šŸŽ“ He holds a Masterā€™s in Clinical Pharmacy and a Bachelorā€™s in Pharmacy from the University of Gondar. šŸ“š With numerous publications in SJR Q1 journals, his research spans AI in pharmacy, mental health, and public health. šŸ§  As a lecturer and former Head of Hospital Pharmacy, he excels in teaching, leadership, and community service. šŸ’Š His commitment to healthcare ethics and professional development makes him a standout in pharmacy research. šŸŒ

Publication Profile

google scholar

Education

Ashenafi Sendekie is a dedicated scholar currently pursuing a Ph.D. in Pharmacy at Curtin University, Australia šŸ‡¦šŸ‡ŗ (2024ā€“present). His research focuses on exploring pharmacists’ experiences and ethical dilemmas in administering vaccines to children and adolescents using a mixed-methods approach šŸ’‰šŸ“Š. He earned a Diploma in Teaching Methodology from the University of Gondar, Ethiopia šŸ‡ŖšŸ‡¹ (2020ā€“2021), and an MSc in Clinical Pharmacy from the same institution (2018ā€“2020) šŸ§ŖšŸ“š. Ashenafi began his academic journey with a Bachelor of Science in Pharmacy from the University of Gondar (2009ā€“2014) šŸŽ“. His commitment to pharmacy and education exemplifies his passion for improving healthcare outcomes šŸŒŸ.

Professional Membership

Ashenafi Sendekie is a proactive professional serving as the Chairperson of the Ethiopian Pharmaceutical Association (EPA), Gondar Chapter Executive Committee, since January 2023 šŸŒšŸ’Š. He is also an active member of the Ethiopian Public Health Association (EPHA) šŸ„. Ashenafi is known for his exceptional skills, including being a fast learner šŸ§ , maintaining a positive attitude šŸŒŸ, and excelling in time management ā³ and attention to detail šŸ”. His strong communication skills šŸ—£ļø, reliability ā°, computer proficiency šŸ’», and teamwork šŸ¤ make him a valuable asset in any setting. Ashenafi’s organizational expertise ensures efficiency and success in his endeavors šŸ“‹āœ”ļø.

Journals Reviewer

Ashenafi Sendekie has actively contributed to renowned international journals as an author and researcher šŸ–‹ļøšŸŒ. His work is featured in prestigious publications, including PLOS Global Public Health šŸŒ, BMJ Open šŸ“–, and Nature (Scientific Reports) šŸ”¬. He has also contributed to journals like Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy šŸ©ŗ, Patient Preference and Adherence šŸ’Š, and BMC Health Services Research šŸ„. Other notable journals include F1000Research šŸ”Ž, BMC Endocrine šŸ’”, Integrated Pharmacy Research and Practice āš•ļø, and BMJ Open Respiratory Research šŸŒ¬ļø. Ashenafiā€™s scholarly efforts reflect his commitment to advancing global health and pharmacy research šŸ“šāœØ.

Collaboration

Ashenafi Sendekie is a committed contributor to the Global Burden of Disease (GBD) Collaboration šŸŒšŸ“Š, based at the Institute for Health Metrics and Evaluation (Hans Rosling Center for Population Health) in Seattle, WA, USA šŸ‡ŗšŸ‡ø. Since December 17, 2024, he has served as a GBD Senior Collaborator šŸŒŸ, following his role as a GBD Collaborator from April 2023 to December 16, 2024 šŸ“ˆ. Ashenafiā€™s work in this global initiative highlights his dedication to advancing population health and contributing to impactful research aimed at improving health outcomes worldwide šŸŒāœØ.

Conferences

Ashenafi Sendekie has actively participated in key academic events and presented his work on an international stage šŸŒšŸŽ¤. He presented a paper at the 5th Annual Conference of the Australian-based Ethiopian Researchers Network (ABReN) on August 31, 2024 šŸ“…. He also took part in the International Pharmaceutical Federation (FIP) PPR SIG 2024 Virtual Meeting on July 4, 2024 šŸ’». Additionally, Ashenafi delivered an oral presentation at the 43rd Annual Conference of the Ethiopian Pharmaceutical Association held in Addis Ababa, Ethiopia, from July 28-29, 2023 šŸ‡ŖšŸ‡¹šŸ’Š. His active involvement highlights his commitment to advancing pharmaceutical research and knowledge sharing šŸ“š.

Honors and Awards

Ashenafi Sendekie has received numerous prestigious awards throughout his academic journey šŸŽ“šŸ†. In November 2023, he was awarded the 2024 HDR Curtin Scholarship at Curtin University, Australia šŸ‡¦šŸ‡ŗ, providing a tuition fee offset and a stipend of $33,220 per annum for three years, with a possible six-month extension šŸ’µ. Earlier, in August 2023, he was offered admission for a Doctor of Philosophy in Pharmacy at Curtin University šŸ§Ŗ. In November 2022, Ashenafi received the Community Service Project Award from the University of Gondar, Ethiopia šŸ‡ŖšŸ‡¹, for his project improving pharmacists’ roles in patient counseling šŸ’¬. He also received research and scholarship grants for his master’s studies in clinical pharmacy šŸ’”.

Current Residence

Ashenafi Sendekie currently resides at UniLodge at Curtin University ā€“ Guild House šŸ , located at 21.2, 63 Jackson Road, Karawara, WA, 6152, Australia šŸ‡¦šŸ‡ŗ. This accommodation provides him with a comfortable and convenient living space close to Curtin University, supporting his academic pursuits šŸ§‘ā€šŸŽ“. As a Ph.D. student in Pharmacy, Ashenafi is able to focus on his studies while enjoying a supportive community environment at UniLodge šŸŒŸ. The location offers access to university facilities and enhances his experience as an international student in Australia šŸŒ.

Research Focus

Dr. Ashenafi Sendekie is a researcher with a strong focus on pharmacology, medication adherence, and chronic disease management. His work investigates the impact of medications, particularly for conditions like type 2 diabetes, asthma, and psychiatric disorders, while emphasizing patient education, medication safety, and adverse drug reactions. Dr. Sendekie also explores healthcare delivery in Ethiopia, including the roles of community pharmacists and the quality of life in patients managing chronic diseases. His research aims to improve medication adherence, reduce drug interactions, and enhance patient outcomes in low-resource settings. šŸ©ŗšŸ’ŠšŸ“Š

Publication Top Notes

Global, regional, and national burden of disorders affecting the nervous system, 1990ā€“2021: a systematic analysis for the Global Burden of Disease Study 2021

Medication adherence and its impact on glycemic control in type 2 diabetes mellitus patients with comorbidity: A multicenter cross-sectional study in Northwest Ethiopia

Assessment of community pharmacy professionalsā€™ knowledge and counseling skills achievement towards headache management: a cross-sectional and simulated-client based mixed study

Evaluation of antibiotics residues in milk and meat using different analytical methods

Impact of personal, cultural and religious beliefs on medication adherence among patients with chronic diseases at university hospital in Northwest Ethiopia

Potential drug-drug interactions and associated factors among admitted patients with psychiatric disorders at selected hospitals in Northwest Ethiopia

Glycemic control in newly insulin-initiated patients with type 2 diabetes mellitus: A retrospective follow-up study at a university hospital in Ethiopia

Incidence and patterns of adverse drug reactions among adult patients hospitalized in the University of Gondar comprehensive specialized hospital: A prospective observationalĀ ā€¦

Mrs. Anke van Engen|Pharmaceutical Policy and Regulation | Best Researcher Award

Published on by Top Pharmaceutical

Mrs. Anke van Engen |Pharmaceutical Policy and Regulation|Best Researcher Award|

Mrs. Anke van Engen atIQVIA,Netherlands

PROFILEĀ Ā 

Scopus

 

Early Academic Pursuits šŸŽ“

Anke van Engen’s academic journey began at the University of Leiden in the Netherlands, where she pursued a Master of Science (MSc) degree in Chemistry, specializing in Bio-organic Chemistry. Her passion for understanding the intricate mechanisms of chemistry and its application to life sciences laid a strong foundation for her future endeavors. Her academic pursuits were not confined to the classroom; she also completed an internship in biochemistry at the Institute of Fundamental Sciences, Massey University in New Zealand, in 1999. This experience provided her with hands-on exposure to research and innovative scientific methodologies, marking the beginning of her profound interest in health economics and outcomes research.

Professional Endeavors šŸ¢

Anke’s professional journey began in 2000 as a PR Assistant at KPN Research, where she gained experience in communications and public relations within the research and innovation sector. However, her true calling was in consultancy, which she pursued by joining Quintiles Consulting in 2001 as an Associate Consultant. Her initial work focused on health economics (HE) modeling, including decision tree and Markov models, patient chart analyses, and market scans. Anke quickly progressed within the company, taking on roles with increasing responsibility, such as Consultant, Senior Consultant, and eventually Consulting Director.

During her time at Quintiles, Anke developed a unique understanding of innovative technologies for supporting clinical and health outcomes studies. She became instrumental in the development of health economic models used in key submissions to organizations like NICE (National Institute for Health and Care Excellence) and SMC (Scottish Medicines Consortium). Her expertise in market access (MA) strategy, value argument development, and health economics led to her appointment as the Principal at Quintiles Advisory Services, where she led the development of the HTA Acceleratorā€”an online platform that became the flagship product for market access solutions.

In 2017, Anke transitioned to IQVIA, where she continued her trajectory of success. She took on roles such as Senior Principal and Managing Principal, leading international teams and developing EMEA-specific offerings in health economics and market access. Her leadership and strategic insights have been crucial in shaping the payer evidence solutions landscape across the EMEA region.

Contributions and Research Focus šŸ§ 

Anke van Engen’s contributions to the field of health economics, outcomes research, and market access are substantial. Her work has focused on developing integrated solutions that provide strategic insights for life sciences companies, enabling them to navigate the complex landscape of health technology assessments (HTAs) and market access requirements. Her leadership in the development of the HTA Accelerator platform has been particularly impactful, offering a comprehensive solution for gathering payer insights and facilitating launch readiness.

Anke’s research focus extends beyond practical applications to thought leadership in the industry. She has consistently contributed to the development of innovative methodologies and best practices in health economics and market access, helping to advance the field and improve the commercial success of pharmaceutical products.

Accolades and Recognition šŸ†

Throughout her career, Anke has received numerous awards and accolades that reflect her expertise and influence in the field. Notable among these are the ISPOR Best Podium and Poster Awards, which she received in 2012 and 2011, respectively, for her work on understanding the complexities of HTA networks and the stakeholder decision-making process in the UK. Her contributions have been recognized at various international conferences, where her issue panels have consistently ranked among the top-attended sessions. In 2014, she won the Sharktank contest for best innovation, securing investment for the HTA Accelerator platformā€”a testament to her innovative thinking and ability to drive impactful solutions.

Impact and Influence šŸŒ

Anke van Engen is widely respected by her colleagues, clients, and the broader industry for her deep expertise, strategic vision, and collaborative approach. Her ability to build long-lasting partnerships with clients and deliver consistent results has made her a trusted advisor in the life sciences sector. She has played a pivotal role in shaping the market access landscape in Europe and beyond, influencing the way companies approach payer evidence strategies.

šŸŽ“PublicationĀ 

Use of External Comparators for Health Technology Assessment Submissions Based on Single-Arm Trials

  • AuthorsĀ  Ā :Patel, D., Grimson, F., Mihaylova, E., … van Engen, A., Kim, J
  • JournalĀ  Ā  :Value in Health
  • YearĀ  Ā  Ā  Ā  Ā :2021